Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.49 |
| ▸ | PRKACA | P17612 | 3/20 | 0.49 |
| ▸ | PLK4 | O00444 | 2/20 | 0.49 |
| ▸ | MARK3 | P27448 | 2/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.49 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.49 |
| ▸ | PRKACG | P22612 | 2/20 | 0.49 |
| ▸ | PRKACB | P22694 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469895 | 1.00 | ROCK2 (0.50) | ROCK2ROCK1PRKCDPRKD3PRKCZ | |
| SCHEMBL14256991 | 0.85 | ROCK2 (0.51) | ROCK2ROCK1PRKCDPRKD3PRKCZ | |
| SCHEMBL12571556 | 0.83 | ROCK2 (0.50) | ROCK2ROCK1PRKCDPRKD3PRKCZ | |
| SCHEMBL2001999 | 0.81 | MAPT (0.41) | ROCK2ROCK1PRKCDPRKD3PRKCZ | |
| SCHEMBL2006560 | 0.80 | ROCK2 (0.34) | ROCK2ROCK1PRKCDPRKD3PRKCZ | |
| SCHEMBL31537 | 0.80 | ROCK2 (0.47) | ROCK2ROCK1PRKCDPRKD3PRKCZ | |
| Iodide SCHEMBL28700199 | 0.79 | ROCK2 (0.46) | ROCK2ROCK1PRKCDPRKD3PRKCZ | |
| Bromide SCHEMBL28709695 | 0.79 | ROCK2 (0.46) | ROCK2ROCK1PRKCDPRKD3PRKCZ | |
| Hydrochloric Acid SCHEMBL7823569 | 0.79 | ROCK2 (0.33) | ROCK2ROCK1PRKCDPRKD3PRKCZ | |
| Hydrochloric Acid SCHEMBL999448 | 0.79 | ROCK2 (0.47) | ROCK2ROCK1PRKCDPRKD3PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227054-B | ROCK kinase inhibitors | 切尔韦洛治疗有限责任公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-3877364-B1 | ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230331696-A1 | SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR | OCUSUN OPHTHALMIC PHARMACEUTICAL (GUANGZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331696-A1 | SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR | OCUSUN OPHTHALMIC PHARMACEUTICAL (GUANGZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | GUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3988544-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070179127-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2007-04-19 | — | — | US | disclosed |
| EP-0885888-B1 | ISOQUINOLINE DERIVATIVES AND DRUGS | HIDAKA HIROYOSHI DR (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-1074545-A1 | ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Hidaka, Hiroyoshi (JP) | 2001-02-07 | — | — | EP | disclosed |
| US-6153608-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| CN-1210521-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO LTD (JP) | 1999-03-10 | — | — | CN | disclosed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | PDE6G, PDE3A, PDE5A | ROCK2 194/4885ROCK1 111/4885PRKCD 2924/4885 |
| US-20070179127-A1 | Sulfonamide compound | MYLK, MYLK2, MYLK3 | ROCK2 332/4885ROCK1 240/4885PRKCD 975/4885 |
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | ROCK1, CIT, ROCK2 | ROCK2 3/4885ROCK1 1/4885PRKCD 503/4885 |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885PRKCD 235/4885 |
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885PRKCD 114/4885 |
| US-20230331696-A1 | SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR | ROCK1, ROCK2, NHERF1 | ROCK2 2/4885ROCK1 1/4885PRKCD 557/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | ROCK2 16/4885ROCK1 11/4885PRKCD 802/4885 |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885PRKCD 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.